Stemedica
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions.
Team
Stemedica has a team of experienced scientists, management and technicians to progress our proprietary technology.
Technology
Stemedica’s proprietary platform technology produces multiple progenitor cell products that meet exacting quality standards required for a cGMP licensed facility.
Trials
Stemedica is currently advancing clinical trials in the United States for several critical medical conditions.
Latest News
Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in Peer-Reviewed Stroke Journal
Study Sponsored by Stemedica Cell Technologies, Inc. SAN DIEGO, Calif. – (September 30, 2019) – Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis...
Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke
Abstract Background and Purpose Stroke is a leading cause of long-term disability. Limited treatment options exist for patients with chronic stroke and substantial functional deficits. The current study examined safety and preliminary efficacy estimates of intravenous...
Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke
Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke - itMSCs were safe and well tolerated in the study - - Results of the study are supportive of advancing clinical program - - Plans are underway to...